IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Washington

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Washington $ 33,108,644.56
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
AcciumBio Sciences, Inc Personalized treatment of glioblastoma multiforme and other cancers $ 65,700.00 $ 178,779.25
Adaptive TCR Corporation Prediction of Anti-TNF Response in Patients with Crohn's Disease   $ 146,958.50
Adaptive TCR Corporation Development of a Pre-symptomatic Biomarker for Type 1 Diabetes   $ 244,479.25
Adaptive TCR Corporation Prediction of Active Disease State in Crohn's Disease   $ 167,559.50
Adaptive TCR Corporation Identification of Immune System Signatures in Patients with Ovarian Cancer   $ 244,479.24
Adaptive TCR Corporation Immune System Profiling as a Measure of Vaccine Efficacy   $ 244,479.24
ADVANCED MEDICAL ISOTOPE CORPORATION Molybdenum-99 $ 205,129.00 $ 39,350.24
ADVANCED MEDICAL ISOTOPE-CORPORATION Brachytherapy   $ 244,479.24
Agave Pharma Inc A novel nucleic acid delivery technology for RNAi therapeutics $ 244,479.24  
Alder Biopharmaceuticals, Inc ALD518 humanized monocional antibody therapeutic project $ 244,479.24  
Allozyne Inc AZ01 treatment of Multiple Sclerosis(MS) $ 244,479.24  
Allozyne Inc AZ17 for the treatment of Crohn's Disease(CD) $ 244,479.24  
Aminex Therapeutics, Inc Polyamine-Based Therapy (PBT) Approach for Head and Neck Cancer $ 6,980.73 $ 237,498.51
Amnis Corporation An Immune Monitoring Test to prevent Kidney Transplant Rejection $ 244,479.25  
Anergix LLC Peptide Delivery for Downregulating the Autoimmune Response in Multiple Sclerosis   $ 244,479.25
AVI BioPharma Inc Duchenne Muscular Dystrophy (DMD) Therapeutic Program $ 244,479.25  
AVI BioPharma Inc Junin Therapeutic Program $ 244,479.24  
AVI BioPharma, Inc. Marburg Therapeutic Program $ 244,479.24  
AVI BioPharma, Inc. Ebola Virus Therapeutic Program $ 244,479.25  
AVI BioPharma, Inc. Influenza (H1Na virus) Therapeutic Program $ 244,479.25  
Blood Cell Storage, Inc. Molecular Diagnostic Nucleic Acid Extraction Device $ 244,479.25  
Blood Cell Storage, Inc. Device to improve efficacy of therapeutic platelets $ 244,479.25  
Calistoga Pharmaceuticals, Inc CAL-263-Therapeutic for Inflammation and Auto-immunity Targeting P13 Kinase Delta $ 244,479.25  
Calistoga Pharmaceuticals, Inc CAL-120-Therapeutics for Solid Tumor Cancers Targeting the P13 Kinase Beta/Delta Pathway $ 244,479.25  
Calistoga Pharmaceuticals, Inc CAL-101-Therapeutic for Hematologic Malignancies and other Cancers $ 244,479.25  
Calypso Medical Technologies, Inc Guiding Therapeutic Radiation of Tumors Without Respiratory Motion $ 244,479.25  
Calypso Medical Technologies, Inc. Guiding Therapeutic Radiation of Tumors With Respiratory Motion $ 244,479.25  
Cancer Targeted Technology,LLC Development of Innovative Enzyme Inhibitors for Cancer Treatment and Imaging $ 59,683.09 $ 124,245.06
CARDIAC DIMENSIONS, INC. Carillon Mitral Contour System $ 244,479.24  
Cell Therapeutics Inc & Subsidiary Pixantrone $ 244,479.24  
Cell Therapeutics Inc & Subsidiary Bisplatinate   $ 244,479.24
Cell Therapeutics, Inc. & Subsidiary BROSTALLICIN $ 244,479.24  
CELL THERAPEUTICS, INC. & SUBSIDIARY OPAXIO $ 244,479.24  
Cerevast Therapeutics, Inc Sonothrombosis $ 153,880.34 $ 90,598.91
CG Therapeutics, Inc Cancer Vaccine Targeting Human Chorionic Gonadotropin $ 239,500.00 $ 4,979.24
Cocrystal Discovery, Inc Influenza: New therapeutic and technology for broad-spectrum antivirals $ 112,530.50 $ 131,948.74
Cocrystal Discovery, Inc Human rhinovirus: New therapeutic and technology for broad-spectrum antivirals $ 168,796.50 $ 75,682.74
Cocrystal Discovery, Inc. Hepatitis C: New therapeutic and technology for broad-spectrum antivirals $ 244,479.24  
Columbia Northwest Pharmaceuticals LLC PTSD   $ 244,479.25
Columbia Northwest Pharmaceuticals, LLC LifePro $ 12,831.00 $ 231,648.25
EKOS Corporation Transfucer Performance Improvement $ 90,579.50  
EKOS Corporation Mach4e Product Development $ 200,704.50  
EKOS Corporation ULTIMA clincal study $ 6,400.00  
Emergent Detection, Inc. BodyKey FatLoss Sensor   $ 229,900.00
Enject, Inc. GlucaPen™ Emergency Auto-Injector for Severe Hypoglycemia $ 244,479.24  
Epigenomics Inc Epi-proColon, an in-vitro diagonistic blood test for colorectal cancer $ 244,479.25  
Etubics Corporation Development of a novel CEA Expressing Adenovirus for Cancer Treatment $ 244,479.24  
Focused Scientific Inc Aldehyde Dehydrogenase Modulators $ 11,475.00 $ 11,757.00
Healionics Corporation Highly Integrative Biomaterial Structures for Therapeutic Devices $ 244,479.25  
Hema Quest Pharmaceuticals Inc Novel Therapy for Cystic Fibrosis (CF) $ 111,169.50 $ 95,967.00
HemaQuest Pharmaceuticals Inc Novel Therapy for Beta-Thalassemia $ 244,479.25  
HemaQuest Pharmaceuticals Inc Novel Therapy for Sickle Cell Disease (SCD) $ 244,479.25  
HemaQuest Pharmaceuticals Inc Novel Treatment for EBV-related Lymphoid Malignancies $ 244,479.25  
Hyprotek, Inc Topical Solutions and Devices for Antimicrobial Action and Reduction of CRBSI $ 8,549.00 $ 11,829.00
Immune Design Corp IDC-G103, a Therapeutic Vaccine for the Treatment of Herpes Simplex Virus Type 2 $ 244,479.25  
Immune Design Corp A Therapeutic Vaccine for Prostate Cancer Based on a Lentivirus Vector Delivery Platform $ 244,479.25  
Impel NeuroPharma, Inc Pressurized Olfactory Delivery (POD) device $ 112,886.11 $ 131,593.14
Implicit Bioscience Inc. Development of IC 14 for acute lung injury $ 10,706.50 $ 233,772.74
Inimex Pharmaceuticals USA, Inc Amelioration of chemotherapy-induced mucositis in cancer patients   $ 244,479.25
Insilicos LLC Diagnosing Cardiovascular Disease Via Molecular Changes to HDL Particles $ 218,730.00 $ 25,749.25
Integrated Diagnostics Inc An In Vivo Diagnostic for Early Detection of Lung Cancer Using Synthetic Antibodies $ 244,479.25  
Intergrated Diagnostics A Molecular Diagnostic Test for the Early Detection of Alzheimer's Disease $ 122,561.50 $ 121,917.75
Intergrated Diagnostics, Inc A molecular Diagnostic Test for the Early Detection of Lung Cancer $ 24,310.00 $ 220,169.25
IsoRay Medical Inc Brachytherapy Utilizing Balloon & Liquid Radiation source for Operable Brain Cancer $ 852.00 $ 234,886.00
IsoRay Medical, Inc APBU using cesium-131 sources following lumpectomy for early stage breast cancer $ 48,911.00 $ 127,308.00
IsoRay Medical, Inc. Cesium-131 Lung Brachytherapy and Sub-Lobar Resection in Stage I NSCLC $ 59,553.00 $ 55,000.00
KINETA ONE, LLC ShK-186 AUTOIMMUNE PROGRAM $ 244,479.25  
Kineta TWO, LLC. Antiviral protein Therapeutic   $ 244,479.25
Kineta, Inc RIG-1 Antiviral Program $ 160,600.44 $ 83,878.81
Koronis Pharmaceuticals Inc KP-1461 An Innovative Therapy for the Treatment and Possible Cure of HIV $ 244,479.25  
Kurve Technology, Inc Controlled Particle Dispersion Technology Platform (CPD) $ 132,374.54 $ 112,104.70
Light Sciences Oncology, Inc Light-Activated Talaporfin Sodium for Primary and Secondary Liver Tumors $ 244,479.25  
Light Sciences Oncology, Inc. Light-Activated Talaporfin Sodium for Treatment of Benign Prostatic Hyperplasia $ 244,479.24  
MDRNA, Inc. RNA-interference (RNAi) Therapeutics $ 244,479.24  
MediQuest Therapeutics, Inc Vascana $ 244,479.24  
Micronics, Inc. Advancement of Novel Molecular Diagnostic Platform for Acute & Chronic Disease Detection $ 244,479.24  
Mirabilis Medica Inc Mirabilis HIFU device for the treatment of uterine fibroids $ 244,479.24  
Mirina Corporation Novel MicroRNA Antagonists for the Treatment of Cancer $ 244,479.24  
Mirina Corporation Novel MicroRNA Antagonists for the Treatment of Fibrotic Liver Disease $ 146,478.18 $ 98,001.06
Nanoquantum Sciences, Inc Development of Novel Photosensitizers with Cellular Targeting for Cancer Therapy $ 51,790.46 $ 192,688.79
NanoString Technologies, Inc. The NanoString nCounter Breast Cancer Subtyping Molecular Diagnostic Test $ 244,479.24  
Nortis Inc. Microvascular assays for research and drug testing in cancer and other diseases $ 28,823.50  
Oasis Diagnostics Corporation Development of a new tool for the collection of DNA from saliva specimens $ 8,130.00 $ 6,237.00
Omeros Corporation Development of PDE7 inhibitor as a novel approach for the treatment of Parkinson's disease. $ 191,898.62 $ 52,580.63
Omeros Corporation Development of Novel Treatment for Addiction $ 64,477.37 $ 54,453.25
Omeros Corporation Development of novel treatments for osteoarthritis and the protection of articular cartilage $ 84,255.58 $ 53,024.81
Omeros Corporation New Drug Product to Treat Pain, Inflammation and Spasm of the Urinary Tract, OMS201 $ 204,440.36 $ 40,038.89
Omeros Corporation MASP-2 MoAb Treatment for Traumatic Injury $ 244,479.25  
Omeros Corporation Development of novel medications for schizophrenia treatment $ 244,479.25  
Omeros Corporation Intracameral OMS302 to Maintain Intraoperative Mydriasis and Reduce Pain and Inflammation $ 208,240.95 $ 36,238.30
Omeros Corporation Novel Drug Product to Improve Function and Reduce Pain Following Arthroscopic Surgery $ 244,479.25  
OncoGenex Pharmaceuticals, Inc. Use of OGX-011 to Enhance the Effects of Chemotherapy in Prostate Cancer $ 244,479.25  
OncoGenex Pharmaceuticals, Inc. Use of OGX-427 to Enhance the Effects of Chemotherapy $ 244,479.25  
Onconome Inc Colon Cancer Rule Out Test $ 117,093.50 $ 113,923.00
Onconthyreon Inc PX-866 PI-3 Kinase Inhibitor $ 244,479.24  
Oncothyreon Inc ONT 10 Novel Therapeutic Cancer Vaccine $ 69,733.00 $ 174,746.24
Ondine Research Laboratories Inc Nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) $ 140,717.01 $ 103,762.24
Onkor Pharmaceuticals, Inc Pivotal study of small cell lung cancer therapeutic agent $ 80,300.00 $ 28,582.50
Onkor Pharmaceuticals, Inc Pivotal study of hepatoma therapeutic agent   $ 1,169.00
Pacific Biomarkers, Inc. PBI Organ Injury Biomarker Initiative $ 73,350.00 $ 171,129.25
Pathway Medical Technologies Inc Jetstream Catheter $ 244,479.25  
PhaseRx, Inc Polymeric Delivery System of Macromolecules (RNA) to Hepatocytes $ 244,479.25  
PhaseRx, Inc. Targeted Therapeutic Delivery Polymers for Oncology Applications $ 121,525.00 $ 122,954.25
PhenoPath Laboratories PLLC Improving and expanding testing available for detecting cancer and other diseases $ 244,479.25  
Poniard Pharmaceuticals, Inc Phase 3 Studies of Picoplatin, a New-Generation Platinum-Based Chemotherapeutic $ 244,479.25  
Presage Biosciences, Inc Development of an In Vivo Assessment Platform for Preclinical and Clinical Testing of Novel Therapeutics $ 17,320.36 $ 227,158.88
ProFibrix Inc PRO-0510: a Fibrin Sealant for Severe Bleeding $ 244,479.24  
Proteo Tech, Inc. Systebryl for the Treatment of Systemic AA Amyloidosis $ 233,727.93 $ 10,751.32
ProteoTech Inc. Synuclere for the Treatment of Parkinson's Disease $ 244,479.25  
ProteoTech, Inc. Pepticlere for the Treatment of Alzheimer's Disease $ 52,550.57 $ 87,197.78
ProteoTech, Inc. PET Imaging for Diagnosis of Parkinson's Disease $ 95,204.31 $ 90,276.21
ProteoTech, Inc. Exebryl-1 for the Treatment of Alzheimer's Disease $ 134,205.07 $ 110,274.18
Qwell Pharmaceuticals, Inc. Development of Avicin D for cancer treatment $ 244,479.25  
RareCyte, Inc. Detection and Characterization of Circulating Tumor Cells $ 244,479.25  
Rhine Pharmaceuticals LLC Symmetrin   $ 244,479.25
Scolr Pharma Inc Oral Dosage Form of Peramivir $ 2,417.00  
SCOLR Pharma nc 24 mg Ondansetron Extended Release Tablets $ 4,191.50  
SCOLR Pharma Inc 600 mg Ibuprofen - Extended Release $ 244,479.24  
Silere Medical Technology, Inc Therapeutic Electrical Neurostimulation Prosthesis for Suppression of Chronic Tinnitus $ 244,479.24  
Sound Pharmaceuticals Inc Otoprotection of noise hearing loss $ 244,479.25  
Sound Pharmaceuticals Inc Regeneration of hearing after sensorineural hearing loss $ 95,123.00 $ 149,356.25
Sound Pharmaceuticals Inc Chemoprotection in chemotherapy receiving cancer patients $ 4,286.00 $ 240,193.25
STB LTD Development of the novel FAST Dressing for Immediate Control of Life Threatening Bleeding $ 244,479.25  
Stratos Genomics Inc SBX™ Genome Analyzer $ 186,876.34 $ 57,602.91
Syntrix Biosystems M1-Tramadol: A new therapeutic for patient to Tramadol   $ 206,169.50
Syntrix Biosystems Development of CXCR1/2 Antagonists for the Treatment of Pulmonary Inflammatory Diseases $ 207,498.73 $ 36,980.52
Syntrix Biosystems L/D-aminopterin as a novel once-weekly oral and low-cost alternative to costly biologics $ 239,613.28 $ 4,865.97
Syntrix Biosystems Inc Snap-To-It Probes $ 151,226.36 $ 93,252.89
Theraclone Sciences, Inc. Theraclone  Anti-M2e Influenza  Monoclonal Antibody Project $ 244,479.24  
Theraclone Sciences, Inc. Theraclone Universal Anti-HIV Monoclonal Antibody Project $ 244,479.24  
Theraclone Sciences, Inc. Theraclone Anti-HA Influenza Monoclonal Antibody Project $ 244,479.24  
Theraclone Sciences, Inc. Theraclone Universal Anti-HCMV Monoclonal Antibody Project $ 166,838.50 $ 77,640.74
Tissue Regeneration Systems, Inc. Resorbable Implant for Bone Replacement and Regeneration in Craniomaxillo Facial Surgery   $ 244,479.24
Trubion Pharmaceuticals Inc TRU-016 $ 244,479.24  
Trubion Pharmaceuticals Inc Annika Vanghagen $ 244,479.24  
Trubion Pharmaceuticals Inc X1 Scorpion $ 244,479.25  
Trubion Pharmaceuticals Inc. TSCORP $ 244,479.25  
Trubion Pharmaceuticals, Inc. X2 Scorpion $ 244,479.25  
Unigen, Inc. Obesity Program $ 229,286.50 $ 15,192.75
Unigen, Inc. UP780 Diabetes Treatment $ 195,924.50 $ 48,554.75
UPTAKE MEDICAL CORPORATION BTVA FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION FOR SEVERE EMPHYSEMA $ 244,479.25  
Viral Logic Systems Technology Corporation Human FcRn Antagonist (FcRn Antagonist) $ 244,479.25  
Viral Logic Systems Technology Corporation VLST is developing a novel product for the treatment of Rheumatoid arthritis (RA) and other chronic inflammatory autoimmune diseases.  VLST's human CD200-Fc agonist therapeutic delivers immunoregulatory signals $ 244,479.25  
Viral Logic Systems Technology Corporation Anti-human Beta-Chemokine Antibody $ 244,479.25  
VisionGate Inc. Microvascular assays for research and drug testing in cancer and other diseases $ 32,318.50 $ 82,685.00
VisionGate Inc. New 3D imaging platform for diagnostic applications in lung cancer and other diseases $ 244,479.25  
VPDiagnostics Inc Non-Invasive Accurate Assessment of Atheroclerosis for Effective Stroke and MI Prevention $ 244,479.25  
XL Sci-Tech, Inc Absorbable and Low-Cost Radioseeds for Malignant Tumors $ 96,780.87 $ 88,629.12
XORI Corporation An Innovative Ex Vivo Platform for Discovery and Optimization of Therapeutic Antibodies $ 244,479.24  
Page Last Reviewed or Updated: 04-Jun-2014